According to Zhitong Finance App, Longshen Rongfa (300534.SZ) issued an announcement. Gansu Pu'an Pharmaceutical Co., Ltd. (hereinafter referred to as “Pu'an Pharmaceutical”), a holding subsidiary of the company, recently received the “Notice of Disapproval of the Drug Marketing Application” issued by the State Drug Administration. The drug is: “bryprazole oral solution”. Reason for disapproval this time: The pharmaceutical registration verification conclusion of this product did not pass. According to the provisions of Article 92 (2) (7) of the “Administrative Measures on Drug Registration”, approval is not granted. Failure to approve the drug's marketing application will not have a significant impact on the company's current results.

According to Zhitong Finance App, Longshen Rongfa (300534.SZ) issued an announcement. Gansu Pu'an Pharmaceutical Co., Ltd. (hereinafter referred to as “Pu'an Pharmaceutical”), a holding subsidiary of the company, recently received the “Notice of Disapproval of the Drug Marketing Application” issued by the State Drug Administration. The drug is: “bryprazole oral solution”. Reason for disapproval this time: The pharmaceutical registration verification conclusion of this product did not pass. According to the provisions of Article 92 (2) (7) of the “Administrative Measures on Drug Registration”, approval is not granted. Failure to approve the drug's marketing application will not have a significant impact on the company's current results.